Difference between revisions of "Rolapitant (Varubi)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: Substance P/neurokinin 1 (NK1) receptor antagonist. <br>Route: PO <br>Extravasation: n/a For conciseness and simplicity, HemOnc.org c...") |
m |
||
| Line 10: | Line 10: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*9/1/2015: Initial FDA approval "in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting sssociated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy." | *9/1/2015: Initial FDA approval "in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting sssociated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy." | ||
| + | |||
| + | ==Pivotal studies== | ||
| + | # Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID, Poma A, Arora S, Kansra V, Schwartzberg LS, Navari RM. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 2015 Sep;16(9):1079-89. Epub 2015 Aug 10. [http://www.ncbi.nlm.nih.gov/pubmed/26272769 PubMed] | ||
==Also known as== | ==Also known as== | ||
Revision as of 17:38, 21 December 2015
General information
Class/mechanism: Substance P/neurokinin 1 (NK1) receptor antagonist.
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Patient drug information
History of changes in FDA indication
- 9/1/2015: Initial FDA approval "in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting sssociated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy."
Pivotal studies
- Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID, Poma A, Arora S, Kansra V, Schwartzberg LS, Navari RM. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 2015 Sep;16(9):1079-89. Epub 2015 Aug 10. PubMed
Also known as
SCH619734, SCH-619734